Published online May 26, 2019. doi: 10.4252/wjsc.v11.i5.236
Peer-review started: January 16, 2019
First decision: January 29, 2019
Revised: February 22, 2018
Accepted: March 26, 2019
Article in press: March 26, 2019
Published online: May 26, 2019
Core tip: Alzheimer’s disease (AD) is a huge burden on the healthcare system and on society. At present, there are no therapeutic approaches that address the underlying causes of this devastating disease, largely because we lack understanding of the underlying molecular mechanisms. Induced pluripotent stem cells (iPSCs) from AD or Down syndrome patients can be used to elucidate these molecular mechanisms, therefore presenting a novel approach to this problem. In this review, we focus on the ability of iPSC models to gain insight into the mitochondrial dysfunction that occurs during AD and therefore identify novel drug targets.